Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernewsroom.regeneron.com
Regeneron Pharmaceuticals Inc. News Releases
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 148 followers
Latest posts
Last updated 4 days ago
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
4 months ago
Normalization of free light chains occurred by day 15 across all doses...
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
4 months ago
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
4 months ago
Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was...
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
3 months ago
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for...
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
3 months ago
Cemdisiran could be the first siRNA approved for the treatment of gMG...
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
3 months ago
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Regeneron Reports Second Quarter 2026 Financial and Operating Results
about 1 month ago
Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter...
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
about 1 month ago
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute...
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FO
24 days ago
FOP is an ultra-rare genetic disorder characterized by rogue bone formation that...
Regeneron Announces Investor Conference Presentations
24 days ago
TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
6 months ago
TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
6 months ago
Approval in moderate-to-severe patients was based on pivotal trial results showing over...